Measures reported in the evidence
- Body weight and waist-related outcomes.
- HbA1c and glucose outcomes in diabetes studies.
- Lipid and liver-fat measures in metabolic-disease substudies.
- Protocol-defined safety laboratory results and adverse events.
Why this is not a personal panel
Which tests are appropriate depends on diagnosis, other medicines, symptoms, and the exact regulated product. A list of trial endpoints cannot safely be converted into individualized monitoring advice.
What this evidence review covers
Describe metabolic and research endpoints measured in trials without creating a personal lab protocol.
- HbA1c and glycemic endpoints in the T2D trial
- Weight and cardiometabolic measures in obesity research
- MRI-PDFF and selected MASLD biomarkers
- Outcome measure versus safety monitoring distinction
- No personal target ranges or testing cadence
Source-backed findings
Each claim below is tied to the evidence class that can support it. Commercial listing data and clinical evidence remain separate.
trial endpoint
The T2D trial's primary endpoint was change in HbA1c, with body-weight endpoints also reported.
substudy endpoint
The MASLD substudy used MRI-PDFF and selected metabolic/liver-related measures in a defined research population.
| Evidence class | What the source supports |
|---|---|
| trial endpoint | The T2D trial's primary endpoint was change in HbA1c, with body-weight endpoints also reported. |
| substudy endpoint | The MASLD substudy used MRI-PDFF and selected metabolic/liver-related measures in a defined research population. |
Source-by-source evidence notes
These notes state what each inspected source can support and the boundary that should not be crossed when interpreting it.
Retatrutide in people with type 2 diabetes - randomized phase 2 trial
Evidence class: primary randomized phase 2. What it supports: n=281 type 2 diabetes trial; HbA1c and body-weight endpoints; gastrointestinal-event reporting.
What it does not establish: Outcomes in people without diabetes, an approved indication, or retail-product equivalence.
Retatrutide for MASLD - randomized phase 2a substudy
Evidence class: primary randomized phase 2a. What it supports: n=98 MRI-PDFF substudy; liver-fat and selected metabolic measurements; substudy design and limitations.
What it does not establish: A liver-disease indication, histologic cure, a universal lab panel, or use of a research-vendor product.
Questions this page answers
Which labs did researchers measure?
List only protocol-defined or publication-reported measures, grouped by study; do not turn them into a personal order set.
What should my values be?
The evidence packet does not establish personal targets or a monitoring schedule; those are clinical questions outside the page's scope.
What remains unresolved
- No validated consumer monitoring panel.
- No target ranges or cadence supported.
- Outcome endpoints must not be mislabeled as required safety labs.